welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
Becker Muscular Dystrophy – A Natural History Study to Predict Efficacy of Exon Skipping
study id #: NCT01539772
condition: Becker Muscular Dystrophy
status: active, not recruitingpurpose:
This is a multi-center natural history study that will be conducted at participating centers in the Cooperative International Neuromuscular Research Group (CINRG). Following a baseline evaluation, participants will have three follow-up visits over a three-year period. The investigators will characterize the Becker muscular dystrophy phenotype, and correlate specific abnormal dystrophin proteins with the range of clinical outcomes.
mechanism of action: Exon-skipping to promote dystrophin production
last updated: November 22, 2018
start date: April 2012
estimated completion: August 2018
size / enrollment: 85
We will utilize the Cooperative International Neuromuscular Research group (CINRG) network to collect cohorts of Becker muscular dystrophy (BMD) patients with in-frame deletions in the dystrophin gene. We will collect clinical data across multiple body systems and correlate these findings to the high-resolution deletion break-point mapping performed from the tissue samples. We will investigate the observed variability to deepen our understanding of molecular mechanisms relevant to the optimization of exon skipping therapeutic approaches.
- Strength and function [Time Frame: Annual]
- Quality of life [Time Frame: Annual]
These questionnaires include:
• Pediatric Quality of Life Inventory (PedsQL)
• Pediatrics and Adult Neuromuscular module Quality of Life (NeuroQOL)
- Medical history assessment - ambulation status, medication history, hospitalizations, surgeries, nutrition, fractures, and cardiac tests [Time Frame: Annual]
• Age 4 or older
• Diagnosis of BMD with an in-frame deletion in the dystrophin gene, where the boundaries of the mutations are confirmed.
Investigator assessment of inability to comply with protocol
Sarepta Therapeutics Announces Positive Expression Results from the Casimersen (SRP-4045) Arm of the ESSENCE StudySarepta Therapeutics, Inc., the leader i...
Solid Biosciences Reports Third Quarter 2018 Financial Results And Provides Business UpdateSolid Biosciences Inc. today reported fi...
“Watching time tick by…”: Decision making for Duchenne muscular dystrophy trialsObjective:This interview study explored ...
A phase 2 trial of the safety and pharmacokinetics of ataluren in patients aged 2 to 5 years with nonsense mutation ...Nonsense mutation Duchenne muscular dyst...
Stem Cell Therapy in Duchenne Muscular DystrophyThe purpose of this study was to study t...
Non-invasive Imaging of Muscle Structure in Duchenne Muscular Dystrophy Using Multispectral Optoacoustic TomographyThis pilot study aims to assess subcellu...
Phase 1/2 Study in Boys With Duchenne Muscular DystrophyThe MoveDMD study is a 3-part, Phase 1/2...
Capricor to Meet with FDA under its RMAT Designation to Discuss HOPE-2 Clinical TrialCapricor Therapeutics announced today th...